Salute e Benessere

Rising Hypertension Rates Boost Blood Pressure Cuffs Market Revenue, Projected…

Increasing awareness about the importance of regular blood pressure monitoring for maintaining overall health is driving market growth. With a growing elderly population worldwide, there is a higher prevalence of hypertension and other cardiovascular diseases, leading to increased demand for blood pressure monitoring devices. Increasing awareness about the importance of regular blood pressure monitoring for maintaining overall health is driving market growth. With a growing elderly population...
PR Newswire
08/07/2024

Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions…

Incorporating blood glucose monitoring into compact and portable smart wearable devices is becoming a major trend. The application provides real-time, convenient, and accurate data reports and health guidance for people monitoring their blood sugar levels. According to a recent report by Grand View Research, the global CGM device market size was approximately $4.6 billion in 2023, with an expected compound annual growth rate of 7.19% from 2024 to 2030. Targeting this emerging market, Goodix…
PR Newswire
08/07/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 08 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
08/07/2024

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™…

UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in UK and EU ISELIN, N.J., July08, 2024(GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc...
Nasdaq GlobeNewswire
08/07/2024

Buyback of Class B shares in Essity during week 27, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
08/07/2024

Orexo: invitation to presentation of the Q2 2024 Interim Report

When registered you will be provided phone numbers and a conference ID to access the conference. When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: https://ir.financialhearings.com/orexo-q2-report-2024 Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations. Contact: Lena Wange, IR & Communications [email protected]+46 (0)18 780 88 00 ...
PR Newswire
08/07/2024

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning…

“Dosing the first patient in the GALAXIES Lung-301 study marks a significant milestone for belrestotug + dostarlimab. iTeos was founded with the goal of advancing therapeutic options for patients by leveraging best-in-class science. The decision to launch our first TIGIT:PD-1 doublet Phase 3 trial underscores our disciplined, data-driven investment approach and was informed by several promising preliminary clinical surrogates such as safety, ORR, and depth of response from the latest...
Nasdaq GlobeNewswire
08/07/2024

Cambrex to Expand Stability Storage Business with New Facility in Durham, North…

Tom Loewald, CEO at Cambrex, stated, "We are thrilled to expand Q1 Scientific's reach into Durham, North Carolina, enhancing our ability to serve pharmaceutical companies across North America. This investment not only broadens our footprint but also leverages Q1 Scientific's extensive expertise in the stability storage business." Tom Loewald, CEO at Cambrex, stated, "We are thrilled to expand Q1 Scientific's reach intoDurham, North Carolina, enhancing our ability to serve…
PR Newswire
08/07/2024

UGREEN Adds Two New Products to Its Nexode Power Bank Family for Ultimate…

Ideal for long-distance travelers, this high-capacity, high-wattage power bank is essential for outdoor adventures. Whether camping or hiking, users will stay powered and connected. It's also perfect for outdoor photographers and videographers, offering continuous power for action cameras. Ideal for long-distance travelers, this high-capacity, high-wattage power bank is essential for outdoor adventures. Whether camping or hiking, users will stay powered and connected. It's also perfect for...
PR Newswire
08/07/2024

A pill for infertility: Oxolife's non-hormonal oral drug raises embryo…

Today, Oxolife is presenting highly promising new data at ESHRE from its proof-of-concept Phase 2 double-blinded, randomised controlled trial of OXO-001, in which it was tested against a placebo pill. Today, Oxolife is presenting highly promising new data at ESHRE from its proof-of-concept Phase 2 double-blinded, randomised controlled trial of OXO-001, in which it was tested against a placebo pill. An exploratory subset analysing 96 women up to 40 years of age, who all underwent single...
PR Newswire
08/07/2024

New4med GmbH Announces First Cases of its novel Basivertebral Nerve Ablation…

BVNA is a treatment for vertebrogenic pain, a type of chronic low back pain associated with bony lesions on the vertebral endplates. The system, approved inEurope, is a minimally invasive, implant-free procedure that can be performed on both inpatient and outpatient bases. It uses targeted radiofrequency energy to block the Nervus basivertebralis from transmitting pain signals to the brain, aiming to improve function and provide sustainable relief. "By offering BVNA to physicians,...
PR Newswire
08/07/2024

SmartCella raises EUR 50 million to accelerate growth and commercialization

The capital raise was supported by existing large institutional investors Fjärde AP-fonden, AMF Pension, and SEB-Stiftelsen, and also included new investors such as AstraZeneca, Handelsbanken Fonder and RoosGruppen AB. Christian Kinch and Thomas von Koch remain major shareholders (via SWIB Holding AB). The capital raise is part of the overall strategic development and future-proofing of SmartCella which includes continued investments in the organization and infrastructure as well as increased…
PR Newswire
08/07/2024

Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx…

Michael Bauer, Partner, Venture Investments, Novo Holdings said: "Myricx has gained unique insights into the biology of NMT and its orthogonal and differentiated mechanism. The scientific rationale behind its novel payload chemistry gives us confidence that NMTi ADCs have the potential to greatly expand the current repertoire of ADC applications beyond the current standard-of-care payload classes, creating opportunities for new treatment options for patients. This investment reflects our…
PR Newswire
08/07/2024

VIRBAC announces executive management changes

Sébastien Huron leaves the company, Habib Ramdani takes over while the Group recruits its next chief executive officer Virbac announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to...
Nasdaq GlobeNewswire
08/07/2024

VIRBAC: exceptional first-half growth and guidance raised for 2024

Compte tenu de ladynamique très positive de nos ventes observée sur le premier semestre(croissance du chiffre d'affaires attendue autour de 16% à taux de change constants 1et ~11% à taux de change et périmètre constants) qui devrait se poursuivre sur le second semestre, ainsi que d'un marché de la santé animale particulièrement porteur,la croissance du chiffre d'affaires 2024 à taux de change constants est attendue entre 12,5% et 14,5% 1(correspondant à une croissance désormais...
Nasdaq GlobeNewswire
08/07/2024

SKF Half-year report to be published on 18 July

To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers. To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers. Link to web event:https://www.investis-live.com/skf/66588e187e7bb30d00b5800f/haewt All information regarding the results will be made available on the Group's IR website:https://investors.skf.com/en/quarterly-reports Media: To book interviews withRickard...
PR Newswire
08/07/2024

Strengthened presence in Europe

Press release Ecully, July 8, 2024 – 8 a.m. Spineway continues its sales and marketing efforts in Europe The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it participated in the38th edition of GEER, the annual congress of the Spanish Spine Society, held in Malaga in May.GEER is the annual meeting of spine surgeons in Spain, like theSFCR Congressheld in Montpellier at the beginning of June. 1...
Nasdaq GlobeNewswire
08/07/2024

Memo Therapeutics AG appoints Paul Carter as Chairperson

PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8July, 2024 – Memo Therapeutics AG(or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to...
Nasdaq GlobeNewswire
08/07/2024

AB Science announces positive results of its Phase 2 study evaluating masitinib…

PRESS RELEASEAB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19Paris, 8 July 2024, 8am CETAB Science SA(Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19.This randomized (1:1), open-label, phase 2 study (AB20001) was designed to evaluate the safety and efficacy of masitinib plus isoquercetin in hospitalized patients with moderate COVID-19 (WHO 7-point ordinal scale level 4) or...
Nasdaq GlobeNewswire
08/07/2024

ESHRE 40th Annual Meeting: Air pollution linked to a decrease in IVF birth rate…

Conducted over an eight-year period in Perth, Australia, the research analysed 3,659 frozen embryo transfers from 1,836 patients. The study examined air pollutant concentrations over four exposure periods prior to oocyte retrieval (24 hours, 2 weeks, 4 weeks, and 3 months), with models created to account for co-exposures. Conducted over an eight-year period inPerth, Australia, the research analysed 3,659 frozen embryo transfers from 1,836 patients. The study examined air pollutant...
PR Newswire
08/07/2024

Hainan Free Trade Port deepens cooperation with Switzerland

During their time in Switzerland, the Hainan delegation held discussions and research meetings with numerous important companies and institutions, including Merck, Richemont, Roche Diagnostics, EHL Hospitality Business School, Switzerland Global Enterprise, the World Trade Organization, and the World Intellectual Property Organization. During their time inSwitzerland, theHainandelegation held discussions and research meetings with numerous important companies and institutions, including...
PR Newswire
07/07/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)PARIS, July05, 2024(GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 06/30/2024100,093,63588,029,364 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] ...
Nasdaq GlobeNewswire
05/07/2024

Inventiva provides an update on its NATiV3 clinical program evaluating…

Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.Analysis of the baseline characteristics of all patients randomized in the main cohort of NATiV3 show a patient profile similar to patients randomized in the NATIVE Phase IIb clinical trial.A blinded analysis of all randomized patients suggests weight gain plateaus and stabilizes between week 24 and 36...
Nasdaq GlobeNewswire
05/07/2024

Virbac : Declaration of the number of shares and voting rights 06/2024

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsJune, 30 20248 458 000Gross total of voting rights :...
Nasdaq GlobeNewswire
05/07/2024
Altri  Comunicati